Using their newly developed acetyl-click screening platform, researchers at Stanford have identified riboflavin analogs as small molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with anti-cancer activity.
Stanford researchers in the Snyder lab have discovered and developed an innovative immunoglobulin modality for the treatment of insulin resistance and type 2 diabetes.
Histone acetyltransferase 1 (HAT1) is an enzyme which acetylates lysine on histone proteins and is intricately involved with regulating gene transcription.